Company Announcement

CLINUVEL

ASX: CUV
Nasdaq International Designation: CLVLY
XETRA-DAX: UR9

CLINUVEL INCLUDED IN S&P/ASX 200 INDEX

S&P Dow Jones Indices announced the inclusion of CLINUVEL in the S&P/ASX 200 Index effective 24 June 2019.

Melbourne, Australia, 14 June 2019

CLINUVEL PHARMACEUTICALS LTD today acknowledges its upgrade from the S&P/ASX 300 Index to the S&P/ASX 200 Index (**XJO**). The inclusion of CLINUVEL in the S&P/ASX 200 Index will be effective 24 June 2019.

S&P Dow Jones Indices undertake periodic rebalancing of a range of indices, including the S&P/ASX 200 Index (XJO) for companies listed on the Australian Securities Exchange (ASX). The S&P/ASX 200 Index is Australia's primary stock market index and is regarded as the benchmark of Australian equity performance.

CLINUVEL met the ranking requirements for the S&P/ASX 200 based on its float-adjusted market capitalisation (including share price history and available ordinary shares on issue) and median liquidity over the past six months.

COMMENTARY

"We view it is a privilege to be selected among Australia's 200 largest listed companies for inclusion in the XJO based on CLINUVEL's recent rise in market capitalisation and trading activity on the ASX," CLINUVEL's Chief Financial Officer, Darren Keamy said. "Underlying this landmark inclusion is the determination and focus of our people to make a difference for patients and their families.

"Over the past year we have witnessed – from the increased trading and significant rise in share price – how CLINUVEL has become a more attractive investable security, particularly to institutions, all on the back of our commercial progress and advancement in R&D. It is business as usual as we work collectively towards a number of important and exciting corporate milestones in 2019 and beyond," Mr Keamy said.

– End –

About CLINUVEL PHARMACEUTICALS LIMITED

CLINUVEL PHARMACEUTICALS LTD (ASX: CUV; NASDAQ INTERNATIONAL DESIGNATION ADR: CLVLY; XETRA-DAX: UR9) is a global biopharmaceutical company focused on developing and delivering treatments for patients with a range of severe genetic and skin disorders. As pioneers in photomedicine and understanding the interaction of light and human biology, CLINUVEL's research and development has led to innovative treatments for patient populations with a clinical need for photoprotection and repigmentation. These patient groups range in size from 5,000 to 45 million worldwide. CLINUVEL's lead compound, SCENESSE® (afamelanotide 16mg), was approved by the European Commission in 2014 for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). More information on EPP can be found at http://www.epp.care. Headquartered in Melbourne, Australia, CLINUVEL has operations in Europe, Switzerland, the US and Singapore, with the UK acting as the EU distribution centre. For more information go to http://www.clinuvel.com.

SCENESSE® is a registered trademark of CLINUVEL PHARMACEUTICALS LTD.

Head of Investor Relations
Mr Malcolm Bull, CLINUVEL PHARMACEUTICALS LTD

Investor enquiries
https://www.clinuvel.com/investors/contact-us

Forward-Looking Statements
This release contains forward-looking statements, which reflect the current beliefs and expectations of CLINUVEL's management. Statements may involve a number of known and unknown risks that could cause our future results, performance or achievements to differ significantly from those expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to develop and commercialise pharmaceutical products, including our ability to develop, manufacture, market and sell biopharmaceutical products; competition for our products, especially SCENESSE® (afamelanotide 16mg); our ability to achieve expected safety and efficacy results through our innovative R&D efforts; the effectiveness of our patents and other protections for innovative products, particularly in view of national and regional variations in patent laws; our potential exposure to product liability claims to the extent not covered by insurance; increased government scrutiny in either Australia, the U.S., Europe and Japan of our agreements with third parties and suppliers; our exposure to currency fluctuations and restrictions as well as credit risks; the effects of reforms in healthcare regulation and pharmaceutical pricing and reimbursement; that the Company may incur unexpected delays in the outsourced manufacturing of SCENESSE® which may lead to it being unable to supply its commercial markets and/or clinical trial programs; any failures to comply with any government payment system (i.e. Medicare) reporting and payment obligations; uncertainties surrounding the legislative and regulatory pathways for the registration and approval of biotechnology based products; decisions by regulatory authorities regarding approval of our products as well as their decisions regarding label claims; any failure to retain or attract key personnel and managerial talent; the impact of broader change within the pharmaceutical industry and related industries; potential changes to tax liabilities or legislation; environmental risks; and other factors that have been discussed in our 2018 Annual Report. Forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation, outside of those required under applicable laws or relevant listing rules of the Australian Securities Exchange, to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. More information on the forecasts and estimates is available on request. Past performance is not an indicator of future performance.

www.clinuvel.com
Level 6, 15 Queen Street T +61 3 9660 4900
Melbourne, Victoria 3000 F +61 3 9660 4999
Australia